目的 探討丹鹿通督片聯(lián)合柳氮磺吡啶治療強直性脊柱炎的臨床療效。方法 選取2015年7月-2016年9在河南省直第三人民醫(yī)院接受治療的強直性脊柱炎患者90例，隨機分為對照組（45例）和治療組（45例）。對照組患者口服柳氮磺吡啶腸溶片，第1周2片/次，第2周3片/次，第3周及以后4片/次，均為2次/d。治療組在對照組的基礎(chǔ)上口服丹鹿通督片，4片/次，3次/d。兩組患者均連續(xù)治療2個月。評價兩組患者臨床療效，同時比較兩組患者治療前后BASDAI、BASFI和臨床癥狀評分以及血清C反應(yīng)蛋白（CRP）、白介素-1β（IL-1β）、IL-4、IL-10和IL-17等血清學(xué)指標變化。結(jié)果 治療后，對照組和治療組總有效率分別為77.78%、95.56%，兩組總有效率比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組BASDAI、BASFI評分均明顯下降（P<0.05）；且治療組這些指標降低水平優(yōu)于對照組（P<0.05）。治療后，兩組下腰背疼痛、外周關(guān)節(jié)疼痛、外周關(guān)節(jié)腫脹等癥狀評分均顯著降低（P<0.05）；且治療組上述臨床癥狀評分降低更顯著（P<0.05）。治療后，兩組CRP、IL-1β、IL-17均顯著降低，而IL-4、IL-10均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組上述血清學(xué)指標改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 丹鹿通督片聯(lián)合柳氮磺吡啶治療強直性脊柱炎的臨床效果顯著，有利于臨床癥狀的改善及降低機體炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Danlu Tongdu Tablets combined with sulfasalazine in treatment of ankylosing spondylitis. Methods Patients (90 cases) with ankylosing spondylitis in Third Provincial Hospital of Henan Province from July 2015 to September 2016 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 2 tablets/time for the first week, 3 tablets/time for the second week, and 4 tablets/time for the third and beyond weeks, twice daily. Patients in the treatment group were po administered with Danlu Tongdu Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and BASDAI, BASFI, and clinical symptom scores, the serological index changes of CRP, IL-1β, IL-4, IL-10, and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.78% and 95.56%, respectively, and there was difference between two groups (P<0.05). After treatment, BASDAI and BASFI scores in two groups were significantly decreased (P<0.05). And these indicators levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of low lumbar back pain, peripheral joint pain, and swelling in two groups were significantly decreased (P<0.05). The decrease degree of clinical symptom score in the treatment group was more significantly than that in the control group (P<0.05). After treatment, CRP, IL-1β, and IL-17 in two groups were significantly decreased, while IL-4 and IL-10 were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement degree of serological indexes in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Danlu Tongdu Tablets combined with sulfasalazine has significant clinical effect in treatment of ankylosing spondylitis, which is conducive to the improvement of clinical symptoms and reduce the inflammatory reaction, and has a certain clinical application value.